


Cynata signs MoU with US biotech company

23 January 2018 | News

Cynata's proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use.



Cynata Therapeutics has signed a Memorandum of Understanding (MoU) with Celularity Inc., a US-based biotech company focusing on regenerative cells and tissues. According to the MoU, Celularity will conduct a commercial evaluation of Cynata's patented Cymerus production method, in order to gauge its effectiveness when combined with Celularity's proprietary therapeutic stem cell technology.

Cellularity is currently developing ways to harness cells from the postpartum placenta to address serious and life-threatening diseases; and utilising strategic assets contributed from Celgene Corporation, Sorrento Therapeutics, United Therapeutics and Human Longevity, Inc.

Australian stem cell and regenerative medicine company Cynata's proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale.

Cymerus utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). As a result of its unique ability, the Cymerus platform therefore provides an off-the-shelf stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale.